Advertisement
UK markets close in 3 hours 48 minutes

  • FTSE 100

    8,119.03
    +40.17 (+0.50%)
     

  • FTSE 250

    19,814.02
    +212.04 (+1.08%)
     

  • AIM

    755.35
    +2.23 (+0.30%)
     

  • GBP/EUR

    1.1672
    +0.0015 (+0.13%)
     

  • GBP/USD

    1.2517
    +0.0006 (+0.05%)
     

  • Bitcoin GBP

    51,264.38
    +265.29 (+0.52%)
     

  • CMC Crypto 200

    1,385.33
    -11.20 (-0.80%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.18
    +0.61 (+0.73%)
     

  • GOLD FUTURES

    2,358.80
    +16.30 (+0.70%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,055.79
    +138.51 (+0.77%)
     

  • CAC 40

    8,044.27
    +27.62 (+0.34%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Moderna’s COVID-19 Trial Delayed: Should Investors Worry?

Prosper Junior Bakiny, The Motley Fool
·4-min read
Moderna’s COVID-19 Trial Delayed: Should Investors Worry?

Moderna (NASDAQ: MRNA) was one of the first companies to kick off a phase 1 clinical trial for its investigational COVID-19 vaccine, mRNA-1273. The trial tested the vaccine's safety, immunogenicity (ability to cause immune system response), and reactogenicity (possible side effects). After getting the green light from the U.S. Food and Drug Administration (FDA), Moderna started a phase 2 trial for mRNA-1273 in May. This trial will test the safety, immunogenicity, and reactogenicity of the vaccine in a pool of 600 healthy participants.

Continue reading